Navigation Links
Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints
Date:1/8/2009

ty is a public health crisis, with more than 70 million Americans considered to be obese, according to the Centers for Disease Control. It is a chronic disease that is linked to serious medical conditions such as Type 2 diabetes, heart disease, blood pressure, stroke, depression and some forms of cancer. Obesity results from an energy imbalance associated with various environmental, behavioral and genetic factors making it a difficult and complicated condition to treat. However, there is a growing understanding of how the central nervous system regulates appetite and metabolism as well as the mechanisms that limit weight loss over time. This understanding is the basis of new strategies in drug development that we believe have the potential to change the way obesity is treated.

About Contrave

Contrave is an investigational oral weight loss medication with a unique mechanism of action that works at two levels within the central nervous system: one designed to control the balance of food intake and metabolism and another designed to control food preference, reward and cravings. We believe that Contrave may be the first treatment for obesity to target these reward centers in the central nervous system. Based on clinical trials completed to date, Contrave is believed to initiate and sustain significant weight loss over one year of treatment by reducing appetite, increasing metabolism and allowing the body to continue losing weight by offsetting its natural tendency to fight back and slow down the weight loss process.

About Orexigen(R) Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead combination product candidates targeted for obesity are Contrave, which is in Phase 3 clinical trials, and Empatic(TM), which is in the later stages of Phase 2 clinical development. Each product candidate is designed to act on
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Orexigen(R) Therapeutics Issued a Key Fourth U.S. Patent on Contrave(R)
2. Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results
3. Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain
4. Orexigen(R) Therapeutics Appoints Dennis Kim, M.D., as Senior Vice President, Head of Obesity and Metabolic Disorders
5. Orexigen(R) Therapeutics to Present at Upcoming Investor Conferences
6. Orexigen(R) Therapeutics Schedules Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2008
7. OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003
8. InteKrin Therapeutics to Present at the 27th Annual JP Morgan Healthcare Conference on Tuesday, January 13
9. Aegera Therapeutics Initiates A Randomized Phase 2 Combination Study of AEG35156 for 1st Line Treatment of Non-Small Cell Lung Cancer
10. Amicus Therapeutics Adds Sol J. Barer, Ph.D. to Board of Directors
11. Cell Therapeutics Announces Receipt of NASDAQ Panel Decision to Transfer to NASDAQ Capital Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2015)... ... July 24, 2015 , ... ... solution, indispensable to any modern scientific or pharmaceutical laboratory. FreezerPro® is an ... Users know precisely where a sample is located even before opening the ...
(Date:7/23/2015)... ... , ... One hundred years ago this year, 18 model airplane clubs competed ... of winning the Henry S. Villard Trophy. The Academy of Model Aeronautics has plans ... to build a Free Flight fantasy club worthy of taking home the Villard Trophy. ...
(Date:7/23/2015)... , July 23, 2015 /PRNewswire/ - Portage Biotech ... PBT.U), and Biohaven Pharmaceutical Holding Company Limited (Biohaven), ... an Investigational New Drug (IND) Application with the ... clinical testing of BHV-0223. Portage holds 54% equity ... BHV-0223 is a glutamate modulating agent and Biohaven ...
(Date:7/23/2015)... (PRWEB) , ... July 23, 2015 , ... Global ... cell research in Santiago, Chile. The symposium will feature some of the world’s ... full day of high-level scientific discussion for medical professionals in general practice. , The ...
Breaking Biology Technology:RURO, Inc. Partners with Integrated Systems Engineering to Provide Comprehensive LIMS Software to Biobanks 2RURO, Inc. Partners with Integrated Systems Engineering to Provide Comprehensive LIMS Software to Biobanks 3RURO, Inc. Partners with Integrated Systems Engineering to Provide Comprehensive LIMS Software to Biobanks 4Academy of Model Aeronautics to Start Online Fantasy Flight Competition 2Portage's Biohaven Announces IND Filing for BHV-0223 for Phase 1 Clinical Testing 2Portage's Biohaven Announces IND Filing for BHV-0223 for Phase 1 Clinical Testing 3Portage's Biohaven Announces IND Filing for BHV-0223 for Phase 1 Clinical Testing 4Global Stem Cells Group Announces Plans to Hold International Symposium on Stem Cells and Regenerative Medicine in Santiago, Chile Sept. 3-4, 2015 2Global Stem Cells Group Announces Plans to Hold International Symposium on Stem Cells and Regenerative Medicine in Santiago, Chile Sept. 3-4, 2015 3
... 2011 Oligomerix, Inc. presented results at the ... demonstrated that tau protein forms neurotoxic oligomers with ... results in tau,s self-fragmentation and in the degradation ... neurotoxic mode-of-action. Furthermore, certain tau oligomer species that ...
... RESTON, Virginia and BRNO, Czech Republic, November 16, ... Institute (MMCI) provides complete diagnostics, treatment, and ... and international patients. MMCI is the only health ... a member of the OECI (Organisation of European ...
... Livestream Info ... http://thehill.com/video/in-the-news/193083-livestreaming-genetic-testing-briefing . , Twitter: ... redefining cancer treatment, and the pace of discovery promises new ... That will be among the topics of discussion today at ...
Cached Biology Technology:A New Mechanism for Tau Protein Pathology in Alzheimer's Disease was Presented by Oligomerix, Inc. at the Society for Neuroscience Annual Meeting 2Masaryk Memorial Cancer Institute Reduces Losses and Administrative Overhead With Ekahau RTLS 2Masaryk Memorial Cancer Institute Reduces Losses and Administrative Overhead With Ekahau RTLS 3Members of Congress, Cancer Experts Address Impact of Genetic Testing on Cancer 2
(Date:7/7/2015)... July 7, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... growing mobile commerce market announces a revised version of one of ... commercial will air on CNBC in New York ... and San Francisco metro areas.    ... on Wocket,s ability to replace all the cards in your wallet ...
(Date:6/30/2015)... To bolster its efforts and commitment to fighting cyber fraud, ... of two new team members. Dimitri ... Raviv will act as head of strategic alliances. These ... the most secure solutions for the enterprise market. ... a provider of security and management products, which was acquired ...
(Date:6/25/2015)... , June 25, 2015 ... Market by Type (Swipe & Area), Technology, Material (Optical ... Healthcare, Commercial Security & Others) & Geography - ... marketsandmarkets, the said market is expected to reach ... 17.1%. Browse 76 market Tables ...
Breaking Biology News(10 mins):Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4
... people breathe while walking in the park, working in the ... spike their blood pressure, a new study suggests. Cardiovascular ... first to report a direct link between air pollution and ... results from these animal studies hold up, this could be ...
... time, next-generation DNA sequencing technologies have been turned on ... each year. The results will help to improve diagnosis, ... new strategies for vaccination. The study sets a ... a disease-causing bacterium: it is the first study of ...
... expectancy for patients with human immunodeficiency virus (HIV) has ... 1990s thanks to advancements in antiretroviral therapy, according to ... and Simon Fraser University in Vancouver, British Columbia. ... drop in AIDS deaths among 43,355 HIV-positive study participants ...
Cached Biology News:OSU study shows exposure to bad air raises blood pressure 2OSU study shows exposure to bad air raises blood pressure 3Defining DNA differences to track and tackle typhoid 2Defining DNA differences to track and tackle typhoid 3Anti-HIV therapy boosts life expectancy more than 13 years 2
BD BioCoat Collagen IV 150 mm Culture Dishes...
Gridded Cell Culture Petri Dish (20 mm molded in base), tissue-culture treated...
MAb to Desmoplakin I & II Desmoplakin I & II...
... PI is used in conjuction with ... in the earlier stages of apoptosis (Annexin ... are in later stages of apoptosis or ... PI is detected in the orange range ...
Biology Products: